The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation

Targeted inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BT...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Discov
Hoofdauteurs: Reiff, Sean D., Mantel, Rose, Smith, Lisa L., Greene, JT, Muhowski, Elizabeth M., Fabian, Catherine A., Goettl, Virginia M., Tran, Minh, Harrington, Bonnie K., Rogers, Kerry A., Awan, Farrukh T., Maddocks, Kami, Andritsos, Leslie, Lehman, Amy M., Sampath, Deepa, Lapalombella, Rosa, Eathiraj, Sudharshan, Abbadessa, Giovanni, Schwartz, Brian, Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6261467/
https://ncbi.nlm.nih.gov/pubmed/30093506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1409
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items